IQVIA (NYSE:IQV) Insider Eric Sherbet Sells 5,000 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider Eric Sherbet sold 5,000 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

IQVIA Price Performance

Shares of NYSE IQV traded down $2.69 during mid-day trading on Friday, hitting $235.09. 1,321,730 shares of the stock traded hands, compared to its average volume of 1,815,732. The company has a market cap of $39.24 billion, a PE ratio of 29.17, a price-to-earnings-growth ratio of 2.20 and a beta of 1.20. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $251.36. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.75. The firm has a 50 day simple moving average of $193.41 and a two-hundred day simple moving average of $186.86.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter in the prior year, the firm earned $2.81 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has initiated a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently bought and sold shares of IQV. Brighton Jones LLC boosted its position in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IQVIA during the 2nd quarter worth approximately $514,000. First Trust Advisors LP increased its stake in shares of IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after acquiring an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of IQVIA by 5.4% during the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after acquiring an additional 1,155 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Royal Bank Of Canada boosted their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. lifted their price target on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday. BMO Capital Markets boosted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Finally, Robert W. Baird raised their price objective on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.